Joanne Bryce - Aug 1, 2023 Form 4 Insider Report for Disc Medicine, Inc. (IRON)

Role
Chief Financial Officer
Signature
By: /s/ Rahul Khara, as Attorney-in-Fact
Stock symbol
IRON
Transactions as of
Aug 1, 2023
Transactions value $
-$221,067
Form type
4
Date filed
8/3/2023, 04:18 PM
Previous filing
Jun 30, 2023
Next filing
Sep 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRON Common Stock Options Exercise $4.57K +4.52K +358.81% $1.01* 5.78K Aug 1, 2023 Direct F1
transaction IRON Common Stock Sale -$152K -3.07K -53.05% $49.63 2.71K Aug 1, 2023 Direct F1, F2
transaction IRON Common Stock Sale -$73.4K -1.45K -53.57% $50.50 1.26K Aug 1, 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IRON Stock Option (Right to Buy) Options Exercise $0 -4.52K -75% $0.00 1.51K Aug 1, 2023 Common Stock 4.52K $1.01 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 he transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 15, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.14 to $50.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.15 to $50.85, inclusive.
F4 The shares underlying this option vest in 16 equal quarterly installments following May 1, 2020, subject to the Reporting Person's continued service on each such vesting date.